Latest Breaking News On - Carbogen amcis - Page 2 : comparemela.com

Ahmedabad (Gujarat) [India], August 11 (ANI/PNN): Dishman Carbogen Amcis Ltd, a fully integrated CRAMS (Contract Research and Manufacturing) company with strong capabilities right from process research and development to late-stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, have announced their first quarter (Q1FY23) results. Financial performance Consolidated Q1FY23 review Consolidated Q1FY23 review - Net revenue was Rs 5,406mn for Q1 FY23 as compared to Rs 5,507mn in the corresponding period of the previous year - EBITDA stood at Rs 904 mn for Q1 FY23 as compared to Rs 1,006 mn during the corresponding period of previous year - EBITDA Margin at 16.7 per cent for Q1 FY23 as against 18.3 per cent in Q1 FY22 - Net Profit stood at Rs 40 mn for Q1 FY23 as compared to Rs 160 mn in the corresponding period of the previous year Q1 FY23Result Highlights - Net Revenue at Rs 5,406 mn in Q1 FY23 down by 1.8 per cent YoY mainly on account of low

Carbogen amcisDishman carbogen amcisHigher developmentContract researchDishman carbogen amcis ltdAhmedabad gujarat indiaUgust 11 ani pnn dishman carbogen amcis ltdA fully integrated crams contract research and manufacturing company with strong capabilities right from process development to late stage clinical commercial supply of api innovator pharmaceutical companiesAve announced their first quarter q1fy23 results financial performance consolidated review net revenue was rs 5406mn for q1 fy23 as compared to rs 5507mn in the corresponding period of previous year ebitda stood at rs 904 mn for q1 fy23 as compared to 1006 mn during the corresponding period of previous year ebitda margin at 16 7 per cent for q1 fy23 as against 18 3 in fy22 net profit stood rs 40 compared to 160 fy23result highlights revenue 5406 mn in q1 fy23 down by 1 8 per cent yoy mainly on account of lower revenues from netherlands business dishman carbogen amcis nce apis and intermediates revenue increased 91 9 primarily due to supplies bavla site driven successful customer audits quats generics 7 demand for these products especially the exports market exceptional operational performance naroda crams 3 0 higher development comprising 70 total quarter cholesterol vitamind analogues decreased 46 bv 39s q1fy22 was almost 38 yearHus extremely front endedHich is not the case this year one of customers last had stocked up huge amount inventory in june quarter ebitda margin at 16 3 per cent q1 fy23 compared to 18 fy22 due higher energy costs and raw material impacted cost base significantly carbogen amcis bv first as same logistics have also globally time fx loss impact approximately rs 9 00 crores part quot other expenses story provided by pnn ani will be responsible any way for content article